DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.

ABSTRACT:

Introduction

Neuroendocrine neoplasms (NEN) are heterogeneous malignancies that can arise at almost any anatomical site and are classified as biologically distinct well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Current systemic therapies for advanced disease, including targeted therapies, chemotherapy, and immunotherapy, are associated with limited duration of response. New therapeutic targets are needed. One promising target is delta-like ligand 3 (DLL3), an inhibitory ligand of the Notch receptor whose overexpression on the surface of NEN is associated with tumorigenesis.

Methods

This article is a narrative review that highlights the role of DLL3 in NEN progression and prognosis, the potential for therapeutic targ

SUBMITTER: Yao J 

PROVIDER: S-EPMC9632312 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature